Biological and Pharmaceutical Bulletin
The Pharmaceutical Society of Japan, established in 1880, is one of Japan’s oldest and most distinguished academic societies. The Society currently has around 18,000 members. It publishes three monthly scientific journals. Chemical and Pharmaceutical Bulletin (Chem. Pharm. Bull.) began publication in 1953 as Pharmaceutical Bulletin. It covers chemistry fields in the pharmaceutical and health sciences. Biological and Pharmaceutical Bulletin (Biol. Pharm. Bull.) began publication in 1978 as the Journal of Pharmacobio-Dynamics. It covers various biological topics in the pharmaceutical and health sciences. A fourth Society journal, the Journal of Health Science, was merged with Biol. Pharm. Bull. in 2012. Yakugaku Zasshi (Japanese for “Pharmaceutical Science Journal”) has the longest history, with publication beginning in 1881. Yakugaku Zasshi is published mostly in Japanese, except for some articles related to clinical pharmacy and pharmaceutical education, which are published in English.
The main aim of the Society’s journals is to advance the pharmaceutical sciences with research reports, information exchange, and high-quality discussion. The average review time for articles submitted to the journals is around one month for first decision. The complete texts of all of the Society’s journals can be freely accessed through J-STAGE. The Society’s editorial committee hopes that the content of its journals will be useful to your research, and also invites you to submit your own work to the journals.

Chairman of Committee
Ken-ichi Hosoya
Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama

Read more
9,148 registered articles
(updated on July 28, 2017)
Online ISSN : 1347-5215
Print ISSN : 0918-6158
Journal home
Featured article
Volume 40 (2017) Issue 7 Pages 1029-1034
Antioxidative Protection of Squalene Adjuvant and Rabies Vaccine with Adjuvant

The authors verified the possibility of antioxidative protection of squalene adjuvant emulsions by the antioxidants α-tocopherol and β-carotene. They determined the influence of β-carotene on the stability and antigenic effectiveness of adjuvant emulsion in combination with rabies vaccine. The composition of the adjuvant emulsions or vaccines was: 2.5% squalene; 6% detergents; 0.5% antioxidant; 91% water phase. The oxidative injury after UV-irradiation was followed by the detection of the peroxide value of the emulsions. The stability of the emulsions was evaluated by the determination of the emulsion’s particle size. The level of rabies antibodies (RAB) in mice sera until day 90 after vaccination, was determined by the rapid fluorescent focus inhibition test. In the in vitro system of squalene adjuvant, α-tocopherol acted as a prooxidant, while β-carotene effectively reduced the oxidative injury. The homogenization of the squalene adjuvant during a prolonged period from 8 to 10 min did not change the particle size. The oxidation processes were efficiently reduced by β-carotene during the preparation process and also during the 70-d storage. The vaccine with β-carotene induced a gradual increase in the RAB levels with the highest value on day 28. While the inactivated rabies vaccine with adjuvant without β-carotene developed a rapid formation of RAB, the application of the vaccine with β-carotene induced a slower but more uniform production of RAB. The level of RAB was significantly higher after the application of the vaccine with β-carotene and reached the protective value of 0.5 IU/mL, in contrast to the vaccine without β-carotene.

Read more
Editor’s picks

The composition of the adjuvant emulsions was 2.5% squalene, 6% detergents, 0.5% antioxidant – α-tocopherol or β-carotene and 91% water phase. Antioxidant effectivity was testing by determination of peroxide value. α-tocopherol acted as a prooxidant, β-carotene was an effective antioxidant. Effectiveness of rabies vaccine with squalene adjuvant was testing on mice. Adjuvanted vaccine with β-carotene was compared to vaccine without antioxidant and induced a slower but prolonged immunity response with protective levels of rabies antibodies (0.5 IU/mL).

View the past featured articles
View all articles in Current issue
Most popular articles Jun.2017
Share this page
Select past volume & issue